SCHEMBL474726

SCHEMBL474726

CCC(F)Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL868159 0.73
SCHEMBL42495 0.73
SCHEMBL868501 0.73
SCHEMBL1973936 0.72
SCHEMBL27401 0.70
SCHEMBL97943 0.70
SCHEMBL5279629 0.68
SCHEMBL1040886 0.67
Water SCHEMBL11060017 0.67 ALDH1A1 (0.33)
SCHEMBL13020450 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3049378-A1 PREPARATION OF RADIOIODINATED 3-FLUOROPROPYL-NOR-BETA-CIT Mallinckrodt LLC (US) 2016-08-03 EP claimed
WO-2015048250-A1 PREPARATION OF RADIOIODINATED 3-FLUOROPROPYL-NOR-BETA-CIT MALLINCKRODT LLC (US) 2015-04-02 WO claimed
EP-1349859-A2 TRIAZOLOPYRIMIDINES Bayer CropScience AG (DE) 2003-10-08 EP claimed
WO-2002050077-A2 TRIAZOLOPYRIMIDINES BAYER CROPSCIENCE AG (DE) 2002-06-27 WO claimed
US-20260091029-A1 VMAT2 INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LUYE INNOMIND PHARMA SHIJIAZHUANG CO LTD (CN) 2026-04-02 US disclosed
US-12565495-B2 VMAT2 inhibitor and preparation method therefor and application thereof LUYE INNOMIND PHARMA SHIJIAZHUANG CO., LTD. (CN) 2026-03-03 US disclosed
EP-3541809-B1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2025-06-25 EP disclosed
CN-115260186-B VMAT2 inhibitor and preparation method and application thereof 山东绿叶制药有限公司 2024-05-28 CN disclosed
EP-4351560-A1 ANTICANCER COMPOUNDS The Regents of the University of California (US) 2024-04-17 EP disclosed
EP-4326718-A1 NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2024-02-28 EP disclosed
WO-2024039861-A1 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER OLEMA PHARMACEUTICALS, INC. (US) 2024-02-22 WO disclosed
EP-4323329-A1 NITROPHENYL-ACRYLAMIDES AND USES THEREOF Brown University (US) 2024-02-21 EP disclosed
WO-1996039198-A1 IODINATED NEUROPROBES FOR MAPPING MONOAMINE REUPTAKE SITES RESEARCH BIOCHEMICALS, LIMITED PARTNERSHIP, doing business as RESEARCH BIOCHEMICALS INTERNATIONAL, A MASSACHUSETTS LIMITED PARTNERSHIP, WHOSE SOLE GENERAL PARTNER IS RBI MANAGEMENT, INC. (US) 1996-12-12 WO disclosed
EP-0718264-A1 A liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition Chisso Corporation (JP) 1996-06-26 EP disclosed
EP-0703791-A4 AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES RES BIOMED LP (US) 1996-05-22 EP disclosed
EP-0703791-A1 AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES RESEARCH BIOMEDICALS LIMITED PARTNERSHIP (US) 1996-04-03 EP disclosed
EP-0656892-A1 HERBICIDAL 2- (4-HETEROCYCLIC-PHENOXYMETHYL)PHENOXY]-ALKANOATES FMC CORPORATION (US) 1995-06-14 EP disclosed
EP-0649413-A1 URACIL DERIVATIVES AS ENZYME INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1995-04-26 EP disclosed
WO-1994001414-A1 URACIL DERIVATIVES AS ENZYME INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1994-01-20 WO disclosed
US-4801750-A Process for the produciton of 2-chloroacetoacetic acid amides LONZA LTD. (CH) 1989-01-31 US disclosed